Ticagrelor is a P2Y12 receptor antagonist and platelet aggregation inhibitor primarily indicated for the prevention of cardiovascular events such as myocardial infarction and stroke in patients with acute… Read more

























Ticagrelor is a P2Y12 receptor antagonist and platelet aggregation inhibitor primarily indicated for the prevention of cardiovascular events such as myocardial infarction and stroke in patients with acute coronary syndrome. This category includes a comprehensive range of reference standards, including the active pharmaceutical ingredient, process-related impurities, degradation products, and stable isotope labelled versions of these compounds. Pharmaceutical laboratories utilize these materials for essential analytical tasks, including impurity profiling, method development, and the validation of analytical procedures required for quality control. By employing these highly characterized standards, researchers can effectively monitor and quantify trace-level impurities, ensuring that drug substances and finished products meet stringent regulatory specifications for safety and therapeutic efficacy. These materials support routine batch release testing and stability studies, facilitating consistent compliance with international pharmacopeial guidelines throughout the drug development lifecycle.